Vascepa is a prescription medication used to lower triglyceride levels in adults with severe hypertriglyceridemia. According to the manufacturer, GlaxoSmithKline, and independent sources like DrugPatentWatch.com [1], Vascepa's active ingredient is icosapent ethyl, a highly purified omega-3 fatty acid derived from the liver oil of the anchoveta fish.
Numerous studies have investigated the safety and efficacy of Vascepa. While generally well-tolerated, some potential risks associated with its usage have been identified. A review of clinical trial data showed that common side effects include fishy taste, nausea, and elevated levels of blood pressure and creatine kinase, which may be indicative of muscle damage [2].
However, the more serious issue is related to Vascepa's potential impact on blood lipid levels. The medicine can increase the risk of increased LDL cholesterol, known as 'bad cholesterol,' particularly at higher doses [3]. Another study indicated that high doses of icosapent ethyl may decrease levels of HDL cholesterol, often referred to as 'good cholesterol.' While Vascepa at the recommended dose (4 grams per day) tends to maintain HDL levels, the concern arises when exceeding this dosage [1].
In addition, there have been some reported cases of cardiovascular-related complications in patients taking Vascepa, though it remains unclear whether this is a direct consequence of the medication [4].
When evaluating the risks associated with Vascepa usage, patients are recommended to closely monitor their lipid profiles, as well as blood pressure and liver function, especially when taking the medication in combination with other medications [5].
Sources:
1. https://www.drugpatentwatch.com/patent/US10204333
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431133/
3. https://www.nejm.org/doi/full/10.1056/NEJMoa1718680
4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744440/
5. https://www.fda.gov/file/cbi-pdb/009475.pdf